GlassScriptPhysician profile
Pedro R Moreno
NPI 1861414096
$53,946.18
in general payments reported to CMS, 2019-2025
26 companies · $6,769 in 2025
The $6,769 reported for 2025 was more than what 86% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,396 · 2020: $4,556 · 2021: $3,706 · 2022: $11K · 2023: $15K · 2024: $6,328 · 2025: $6,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Consulting Fee: $8,000 · Grant: $5,000 · Food and Beverage: $3,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,000.00 |
| Consulting Fee | $8,000.00 |
| Grant | $5,000.00 |
| Food and Beverage | $3,181.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22,150.00 | 2021-2024 | Symplicity G3 |
| Abbott Laboratories | $13,828.40 | 2019-2025 | Optis, Ensite Precision, Pressurewire |
| Boston Scientific Corporation | $5,131.32 | 2019-2024 | |
| Medtronic Vascular, INC. | $5,006.88 | 2019-2020 | |
| Amgen INC. | $3,082.61 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $1,362.96 | 2019-2025 | Wainua, Andexxa |
| Abiomed | $971.88 | 2019-2023 | Impella |
| Provisio Medical, INC. | $741.73 | 2023-2024 | |
| Philips North America LLC | $277.02 | 2019 | |
| Shockwave Medical, INC | $255.59 | 2025 | |
| Heartflow, INC. | $229.78 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.00 | 2025 | |
| Cook Medical LLC | $133.97 | 2023 | Cook |
| Edwards Lifesciences Corporation | $124.71 | 2019 | |
| Pfizer INC. | $121.47 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $63.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $50.61 | 2021-2022 | |
| Scpharmaceuticals INC. | $44.68 | 2025 | |
| Gilead Sciences, INC. | $39.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.38 | 2024 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $33.64 | 2024 | Arcalyst |
| Braemar Manufacturing, LLC | $26.45 | 2019 | |
| Cardiva Medical, INC. | $25.23 | 2023 | Cardiva Vascade 5f Vcs |
| Novartis Pharmaceuticals Corporation | $20.72 | 2024 | |
| Terumo Medical Corporation | $19.19 | 2019 | |
| Janssen Biotech, INC. | $14.63 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$41,610.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.